



Translational Genomics Research Institute milestones:

- 2002** – Dr. Jeffrey Trent returns to Arizona to become President and Scientific Director of the Translational Genomics Research Institute. Most recently, Dr. Trent has worked since 1993 as the Scientific Director of the National Institutes of Health’s National Human Genome Research Institute in Bethesda, Md.
- 2002** – Scientists from across the globe converge in the Valley to start work at TGen.
- 2002** – TGen establishes a Board of Directors, including the Arizona Governor, the Chairman of the Arizona Board of Regents and the Presidents of Arizona State University, University of Arizona and Northern Arizona University.
- 2003** – TGen begins working with the Southwest Autism Research & Resource Center (SARRC) to research autism, the first of more than 1,000 partnerships and collaborations signed by TGen.
- 2003** – TGen partners with Phoenix and with the Salt River Pima-Maricopa Indian Community to study the genetic basis of diabetes and other debilitating diseases.
- 2003** – Scientists from TGen, ASU and NAU complete the DNA sequencing of the Arizona plague.
- 2003** – First international agreement signed with Mexico’s Consortium for the Institute of Genomic Medicine (INMEGEN) to conduct research into regional diseases.
- 2004** – TGen welcomes first class of summer interns.
- 2004** – Researchers identify a gene linked to sudden infant death syndrome (SIDS).
- 2004** – Cox Communications donates \$3 million towards TGen research, the largest such gift in Cox history.
- 2005** – TGen moves into state-of-the-art headquarters at 445 N. Fifth St. in downtown Phoenix. More than 500 guests attend dedication.
- 2005** – Bio-IT World magazine names TGen a grand prize winner of its annual Best Practices Awards Program, which identifies the best strategies, technologies and practices in research and drug discovery.
- 2005** – Mayo Clinic Collaborative Research Building opens in Scottsdale, Ariz., housing TGen’s Cancer Drug Development Laboratory (CDDL) and TGen’s Drug Development Services (TD2).
- 2005** – TGen and Scottsdale Healthcare launch TGen Clinical Research Services (TCRS), providing a clinical drug trials research site for TGen.
- 2006** – TGen investigators identify the genetic basis of a new type of childhood epilepsy.
- 2006** – TGen and NAU open TGen North, a pathogen genomics and bio-defense research lab in Flagstaff, Ariz.
- 2006** – TGen’s Drs. Jeffrey Trent, John Carpten and Spyro Mousset identify a gene called EphB2 as a risk factor for prostate cancer in African American men.
- 2006** – Arizona Legislature appropriates \$7.1 million to fund TGen autism research.
- 2006** – TGen researchers discover a gene that plays an important role in memory.
- 2006** – An independent study shows that, by 2025, TGen’s annual economic impact on Arizona’s economy will be \$202 million, resulting in 3,125 jobs, nearly \$17 million in tax revenues, and a broadening of the state’s knowledge-based economy.



- 2007** – TGen researchers identify a gene called PVT1 that strongly predicts the risk of end-stage renal disease, in which the kidneys fail prematurely.
- 2007** – A research team led by TGen identifies a gene called GAB2 that may be linked to increased risk of Alzheimer’s disease.
- 2007** – TGen signs a first-of-its-kind agreement with the Salt River Pima-Maricopa Indian Community to investigate the prevalence of kidney cancer.
- 2007** – The Virginia G. Piper Charitable Trust and Flinn Foundation join with Nobel Laureate Dr. Lee Hartwell, the Biodesign Institute at ASU and TGen in creating a \$45 million initiative – the Partnership for Personalized Medicine – a global effort to improve patient care and reduce healthcare costs.
- 2007** – TGen and NAU awarded federal grant to develop bio-warfare disease diagnostic.
- 2008** – Helios Education Foundation awards \$6.5 million, and makes 25-year commitment, to TGen summer internship program.
- 2008** – TGen forges strategic alliance with Mayo Clinic to foster cancer research.
- 2008** – Clinical trials produce key breakthroughs in efforts to treat and someday cure basal cell carcinoma and pancreatic cancer.
- 2008** – TGen announces unprecedented partnership with the government of Luxembourg to accelerate biomedical research, specifically in lung cancer and tissue banking.
- 2008** – TGen scientists uncover new field of research that could help police in crime scene forensics.
- 2008** – TGen and Washington University researchers discover new approach to treating endometrial cancer that actually kills cancer cells in tumor tissues.
- 2008** – TGen investigators devise faster, less expensive way of analyzing the human genome, leading the way toward advancing next-generation gene sequencing.
- 2008** – TGen assists other groups in organizing the first of its kind cancer awareness conference in northeastern Arizona for the Navajo Nation.
- 2008** – TGen and ASU celebrate the startup of Saguaro II, a new supercomputer that can conduct 50 trillion mathematical operations per second, one of the world’s fastest.
- 2009** – TGen sponsors first major national medical conference, highlighting the institute’s contributions to molecular oncology for cancer patients and their doctors.
- 2009** – TGen and ASU researchers discover that the drug Fasudil, used to improve blood flow to the brain in cases of stroke, also could help improve learning and memory and reduce the risk of Alzheimer's disease.